Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 2;9(1):1770565. doi: 10.1080/2162402X.2020.1770565

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Potentiation of the anti-tumor effect of anti-CD20 antibody upon combination with no-alpha mutein. (a), Schematic representation of cytokines monotherapy treatment schedule. (b), IL-2 and no-alpha mutein have no antitumor effect in C57Bl/6 mice injected with EL4-huCD20 cells; IL-2 (n = 17), no-alpha (n = 17), and PBS (n = 12). (c), Schema of combined treatment schedule. (d), Survival curves of mice with the different treatments as indicated; CD20 + IL-2 (n = 45), CD20 + no alpha (n = 45), CD20 (n = 21) and IgG2a (n = 21). Data correspond to two (b) and three (d) independent pooled experiments (log-rank test; *, P < .05; **, P < .01; ***, P < .001; ns: not significant).